文献速递免疫规划慢病防控与筛查

四价人乳头瘤病毒疫苗针对肛门生殖器疣的有效性:基于200万个体登记的研究

Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
PubMed 文献 · Vaccine · 2023-07-27

挪威2009年起为12-13岁女孩常规接种四价HPV疫苗,本研究基于2006-2016年登记数据,分析1975-2003年出生队列。结果显示首次接种年龄≤13岁者肛门生殖器疣风险约为未接种者的0.2倍,疫苗对已发生首次肛门生殖器疣者不预防第二次发作,未接种男性中观察到群体效应。

要点

  • 首次接种年龄≤13岁者肛门生殖器疣风险约为未接种者的0.2倍。
  • 20岁后接种的女性中疫苗效果不显著。
  • 已发生首次肛门生殖器疣后接种不预防第二次发作。

核心结论

  • 14岁前接种四价HPV疫苗可使肛门生殖器疣风险降低约五倍。
  • 疫苗效果随接种年龄增大而急剧下降,20岁后接种的女性中不显著。
  • 首次肛门生殖器疣发作后接种四价HPV疫苗不预防第二次发作。
  • 未接种男性中观察到群体效应,自1993年男性出生队列起肛门生殖器疣发生率逐渐下降。

研究设计与样本

  • 基于登记的研究,收集2006-2016年出生队列1975-2003年的四价HPV疫苗接种与肛门生殖器疣发作数据。
  • 采用Cox模型分析首次及第二次肛门生殖器疣发作时的年龄。
  • 估计女性疫苗接种规划对未接种男性的影响。

主要发现

  • 与未接种者相比,首次接种年龄≤13、14-15、16-17、18-19、20-24、25-29、30+岁组的风险比分别为0.2、0.2、0.3、0.5、1.0、1.3、2.7。
  • 已发生首次肛门生殖器疣的女性中,首次接种年龄≤17、18-24、25+岁组针对第二次发作的风险比分别为0.8、1.0、1.4。
  • 未接种男性队列中肛门生殖器疣风险逐渐降低,邻近首批常规接种女性1997年出生队列。
  • 自1993年男性出生队列起,未接种男性中肛门生殖器疣发生率逐渐下降。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination for girls at 12-13 years of age to protect against virus types causing cervical cancer, HPV16/18, and HPV6/11 which cause anogenital warts (AGW). We wanted to investigate qHPV vaccine effectiveness (VE) against AGW in females before and after first AGW episode and to assess the impact of female vaccination in males. MATERIALS AND METHODS: QHPV vaccination and AGW episodes were collected for the time period 2006-2016 for birth cohorts 1975-2003. Cox models were applied to age at first, as well as at second AGW episode. Finally, we estimated the impact of the female vaccination program on unvaccinated males. RESULTS: The VE against the first episode of AGW was strongly dependent on vaccination age, with hazard ratios (HRs) compared to unvaccinated individuals of 0.2, 0.2, 0.3, 0.5, 1.0, 1.3, and 2.7, for age groups of ⩽13, 14-15, 16-17, 18-19, 20-24, 25-29, and 30+ years at first vaccination, respectively. Among women who had suffered a first episode of AGW, subsequent qHPV vaccination did not protect against a second episode, with HRs of 0.8, 1.0, and 1.4, for age groups of ⩽17, 18-24, and 25+ years at first vaccination. A gradually decreasing AGW risk was seen in unvaccinated male cohorts neighboring the first routinely vaccinated female 1997 cohort. CONCLUSIONS: When administered before 14 years of age, qHPV vaccination reduced the probability of AGW about fivefold. The effect decreased sharply with vaccination age, and was not significant among women vaccinated after age 20 years. QHPV administered after the first AGW episode did not protect against a second AGW episode. Herd effects were indicated in unvaccinated males, as we observed a gradual decrease in AGW rates from the 1993 male birth cohort and onwards.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nygård S, Nygård M, Orumaa M, et al. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals. Vaccine. 2023. PMID: 37516572. doi:10.1016/j.vaccine.2023.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。